As a member of the cyclin-dependent kinases inhibitors (CDKI) and a negative regulatory factor in cell cycle, p57kip2 may interfere with cell cycle progression via blocking the progression in the G1 phase, exerting an anti-tumor effect [4]. This evidence concerns the gene CDKN1C and neoplasm.